Yujiro Ueda
Higashi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).
Journal: Therapeutic advances in medical oncology
Published: October 31, 2025
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study.
Journal: Therapeutic advances in medical oncology
Published: June 26, 2025
Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy.
Journal: International journal of hematology
Published: May 28, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Journal: Frontiers in oncology
Published: May 11, 2025
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid.
Journal: International journal of cancer
Published: April 06, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).
Journal: Therapeutic advances in medical oncology
Published: November 21, 2024
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies.
Journal: Oncology
Published: August 13, 2024
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study.
Journal: Asia-Pacific journal of clinical oncology
Published: July 25, 2024
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Journal: Scientific reports
Published: March 04, 2024
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Journal: Scientific reports
Published: February 24, 2024
Last Updated: 09/26/2026